Is Alpha Cognition Inc. (ACOG) Halal?

NASDAQ Healthcare Canada $110M
✗ NOT HALAL
Confidence: 90/100
Alpha Cognition Inc. (ACOG) is Not Halal under AAOIFI Standard 21. While the debt ratio of 0.7% is acceptable, the cash and interest-bearing securities ratio of 38.6% exceeds the 30% threshold. Alpha Cognition Inc. operates in the Healthcare sector.

Shariah Screening — 5 Standards

Based on financial data from December 2024

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 0.7%
/ 30%
38.6%
/ 30%
0.2%
/ 30%
N/A ✗ NOT HALAL
DJIM 0.7%
/ 33%
38.6%
/ 33%
0.2%
/ 33%
N/A ✗ NOT HALAL
MSCI 1.8%
/ 33%
95.7%
/ 33%
0.5%
/ 33%
N/A ✗ NOT HALAL
S&P 0.7%
/ 33%
38.6%
/ 33%
0.2%
/ 33%
N/A ✗ NOT HALAL
FTSE 1.8%
/ 33%
95.7%
/ 33%
0.5%
/ 50%
N/A ✗ NOT HALAL

Financial Highlights

EPS
$-1.17
P/B Ratio
2.4
EV/EBITDA
-4.7
EV: $81M
Revenue
$0
Beta
2.6
High volatility
Current Ratio
6.7

Profitability

Gross Margin 76.9%
Operating Margin -187.0%
Net Margin -262.2%
Return on Equity (ROE) -125.7%
Return on Assets (ROA) -42.2%

Cash Flow & Balance Sheet

Operating Cash Flow-$8M
Free Cash Flow-$8M
Total Debt$911,463
Current Ratio6.7
Total Assets$51M

Price & Trading

Last Close$5.34
50-Day MA$5.59
200-Day MA$7.22
Avg Volume65K
Beta2.6
52-Week Range
$3.75
$11.54

About Alpha Cognition Inc. (ACOG)

CEO
Mr. Michael E. McFadden B.B.A.
Sector
Healthcare
Industry
Biotechnology
Country
Canada
Exchange
NASDAQ
Market Cap
$110M
Currency
USD

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is Alpha Cognition Inc. (ACOG) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), Alpha Cognition Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is Alpha Cognition Inc.'s debt ratio?

Alpha Cognition Inc.'s debt ratio is 0.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.8%.

What are Alpha Cognition Inc.'s key financial metrics?

Alpha Cognition Inc. has a market capitalization of $110M. The company maintains a gross margin of 76.9% and a net margin of -262.2%. Return on equity stands at -125.7%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.